Pharmafile Logo
Pharmafocus logo
Advanced Search

Xeljanz

Showing 14 posts of 14 posts found.

shutterstock_79370437

New ICER report reveals most cost-effective rheumatoid arthritis therapies

November 27, 2019
Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …

News

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

February 21, 2019
Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …

News

Pfizer notches two EU approvals, including Herceptin biosimilar

August 1, 2018
Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma

Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …

News

Pfizer’s Xeljanz scores EU approval for active psoriatic arthritis

June 29, 2018
Medical Communications, Sales and Marketing EU, Europe, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has announced that the European Commission (EC) has approved Xeljanz in combination with methotrexate (MTX) for the treatment of …

News

Pfizer’s Xeljanz becomes first JAK inhibitor approved in US for active ulcerative colitis

May 31, 2018
Sales and Marketing FDA, Pfizer, US, Xeljanz, pharma, ulcerative colitis

Pfizer has revealed that its Janus kinase (JAK) inhibitor Xeljanz (tofacitinib) has received FDA approval for the treatment of adult …

News

FDA approves Pfizer’s Xeljanz for psoriatic arthritis

December 18, 2017
Sales and Marketing FDA, Pfizer, Xeljanz, pharma, psoriatic arthritis

Pfizer has revealed that the FDA has passed marketing approval for Xeljanz (tofacitinib) for the treatment of active psoriatic arthritis …

News

Pfizer launches legal action to block Xeljanz copies in India

September 9, 2016
Medical Communications, Sales and Marketing Pfizer, Sun Pharma, Xeljanz, Zydus Cadila, rheumatoid arthritis

Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts …

News
pfizer_reflection

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …

News

Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial

July 29, 2016
Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis

Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …

News
pfizerbrussels

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016
Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …

News

EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis

March 24, 2016
Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis

Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …

News
Pfizer image

Pfizer posts fourth-quarter revenue decline

January 28, 2015
Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate

Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …

News

Pfizer’s Xeljanz rejected in Europe

April 28, 2013
Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis

Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023